Paper23945239
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.
Johnson L and 27 others. J Clin Invest, 2013. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. Papers, record 23945239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23945239
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.
- PubMed
Topics25
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiogenesis Inhibitors | Major topic |
| Antibodies | Major topic |
| Apoptosis | Major topic |
| Endothelial Growth Factors | Major topic |
| Human Umbilical Vein Endothelial Cells | Major topic |
| Vascular Endothelial Growth Factor A | Major topic |
| Animals | |
| Antibodies, Monoclonal, Humanized | |
| Bevacizumab | |
| Calcium-Binding Proteins | |
| Carcinoma, Non-Small-Cell Lung | |
| Clinical Trials, Phase I as Topic | |
| EGF Family of Proteins | |
| Humans | |
| Insulinoma | |
| Lung Neoplasms | |
| Mice | |
| Mice, Nude | |
| Mice, Transgenic | |
| Neoplastic Cells, Circulating | |
| Neoplastic Stem Cells | |
| Pancreatic Neoplasms | |
| Tumor Burden | |
| Tumor Cells, Cultured | |
| Xenograft Model Antitumor Assays |
Source PubMed
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17626061 | EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. | Development | 2007 | https://conductscience.org/library/papers/17626061 | PubMed |
| 2 | 15215160 | Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. | Am J Pathol | 2004 | https://conductscience.org/library/papers/15215160 | PubMed |
| 3 | 22611036 | Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. | J Pathol | 2012 | https://conductscience.org/library/papers/22611036 | PubMed |
| 4 | 19144677 | The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. | Oncologist | 2009 | https://conductscience.org/library/papers/19144677 | PubMed |
| 5 | 20947685 | Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. | Blood | 2010 | https://conductscience.org/library/papers/20947685 | PubMed |
| 6 | 15162510 | Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. | Dev Dyn | 2004 | https://conductscience.org/library/papers/15162510 | PubMed |
| 7 | 20213100 | Expression and clinical significance of EGFL7 in malignant glioma. | J Cancer Res Clin Oncol | 2010 | https://conductscience.org/library/papers/20213100 | PubMed |
| 8 | 9238051 | Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. | Proc Natl Acad Sci U S A | 1997 | https://conductscience.org/library/papers/9238051 | PubMed |
| 9 | 15709162 | 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/15709162 | PubMed |
| 10 | 19861458 | Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19861458 | PubMed |
| 11 | 17934064 | Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death. | Am J Physiol Lung Cell Mol Physiol | 2008 | https://conductscience.org/library/papers/17934064 | PubMed |
| 12 | 18854571 | Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18854571 | PubMed |
| 13 | 18268320 | Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18268320 | PubMed |
| 14 | 15085134 | The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. | Nature | 2004 | https://conductscience.org/library/papers/15085134 | PubMed |
| 15 | 22330688 | Antiangiogenic therapy--evolving view based on clinical trial results. | Nat Rev Clin Oncol | 2012 | https://conductscience.org/library/papers/22330688 | PubMed |
| 16 | 16585151 | Contributions of human tumor xenografts to anticancer drug development. | Cancer Res | 2006 | https://conductscience.org/library/papers/16585151 | PubMed |
| 17 | 22593194 | Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. | Cancer Res | 2012 | https://conductscience.org/library/papers/22593194 | PubMed |
| 18 | 20495549 | Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. | Nat Biotechnol | 2010 | https://conductscience.org/library/papers/20495549 | PubMed |
| 19 | 10100573 | A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. | Bone Marrow Transplant | 1999 | https://conductscience.org/library/papers/10100573 | PubMed |
| 20 | 7168798 | Random-effects models for longitudinal data. | Biometrics | 1982 | https://conductscience.org/library/papers/7168798 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37957249 | Low EGFL7 expression is associated with high lymph node spread and invasion of lymphatic vessels in colorectal cancer. | Sci Rep | 2023 | https://conductscience.org/library/papers/37957249 | PubMed |
| 35721105 | Recombinant EGFL7 Mitigated Pressure Overload-Induced Cardiac Remodeling by Blocking PI3K γ /AKT/ NFκB Signaling in Macrophages. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35721105 | PubMed |
| 33262827 | MicroRNA-126: A new and promising player in lung cancer. | Oncol Lett | 2021 | https://conductscience.org/library/papers/33262827 | PubMed |
| 32191808 | The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models. | Blood Adv | 2020 | https://conductscience.org/library/papers/32191808 | PubMed |
| 30065025 | EGFL7 enhances surface expression of integrin α5β1 to promote angiogenesis in malignant brain tumors. | EMBO Mol Med | 2018 | https://conductscience.org/library/papers/30065025 | PubMed |
| 29636300 | Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. | Clin Colorectal Cancer | 2018 | https://conductscience.org/library/papers/29636300 | PubMed |
| 29483510 | EGFL7 reduces CNS inflammation in mouse. | Nat Commun | 2018 | https://conductscience.org/library/papers/29483510 | PubMed |
| 29438092 | Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. | Oncologist | 2018 | https://conductscience.org/library/papers/29438092 | PubMed |
| 28980146 | Egfl7 Represses the Vasculogenic Potential of Human Endothelial Progenitor Cells. | Stem Cell Rev Rep | 2018 | https://conductscience.org/library/papers/28980146 | PubMed |
| 28799610 | Viral nanoparticles decorated with novel EGFL7 ligands enable intravital imaging of tumor neovasculature. | Nanoscale | 2017 | https://conductscience.org/library/papers/28799610 | PubMed |
| 28539619 | Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. | Sci Rep | 2017 | https://conductscience.org/library/papers/28539619 | PubMed |
| 28533390 | Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/28533390 | PubMed |
| 28275117 | Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. | Oncologist | 2017 | https://conductscience.org/library/papers/28275117 | PubMed |
| 27535973 | Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. | Mol Cancer Ther | 2016 | https://conductscience.org/library/papers/27535973 | PubMed |
| 27446447 | High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer. | Oncol Lett | 2016 | https://conductscience.org/library/papers/27446447 | PubMed |
| 26775688 | Ten years of anti-vascular endothelial growth factor therapy. | Nat Rev Drug Discov | 2016 | https://conductscience.org/library/papers/26775688 | PubMed |
| 25705891 | A distinct mechanism of vascular lumen formation in Xenopus requires EGFL7. | PLoS One | 2015 | https://conductscience.org/library/papers/25705891 | PubMed |
| 25601901 | Notching on Cancer's Door: Notch Signaling in Brain Tumors. | Front Oncol | 2014 | https://conductscience.org/library/papers/25601901 | PubMed |
| 25142627 | High expression of epidermal growth factor-like domain 7 is correlated with poor differentiation and poor prognosis in patients with epithelial ovarian cancer. | J Gynecol Oncol | 2014 | https://conductscience.org/library/papers/25142627 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFL7 | 51162 | PubTator's text mining | https://conductscience.org/library/genes/51162 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23945239
GET https://conductscience.org/api/papers/v1/23945239/authors?page=2